Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cassava Sciences, Inc.

Latest From Cassava Sciences, Inc.

BioAge Puts VC Muscle Behind Phase II Azelaprag Trials In Obesity

The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.

Financing StartUps and SMEs

Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent

Zydus MD Sharvil Patel talks to Scrip about a pipeline-in-a-drug approach for novel molecules like ZYIL-1, the intent behind deals with Daewoong and LiqMeds and expected timelines for trial readouts of its PBC/NASH candidate saroglitazar

Commercial Clinical Trials

Intas And mAbxience Strike Global Etanercept Deal

Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.

Deals Biosimilars

Chinese ADC Developers Forge Domestic Alliances To Push R&D

To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.

China Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Pain Therapeutics, Inc.